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ABSTRACT
We prospectively estimated the prevalence of the polycystic ovary
syndrome (PCOS), as defined by the NIH/NICHHD 1990 endocrine
criteria, in a population of 154 Caucasian women of reproductive age
reporting spontaneously for blood donation. Anthropometric data; the
presence of hirsutism, acne, and androgenic alopecia; and the men-
strual history were recorded by a single investigator. In 145 women,
blood samples were also obtained for measurement of serum androgen
levels. PCOS was defined by the presence of 1) oligomenorrhea, 2)
clinical and/or biochemical hyperandrogenism, and 3) exclusion of
hyperprolactinemia, thyroid disorders, and nonclassic 21-hydroxy-
lase deficiency. Hirsutism was defined by a modified Ferriman-
Gallwey score of 8 or more, acne was considered as a sign of hyperan-
drogenism when persistent after the second decade of life, and hy-
perandrogenemia was defined by an increase in circulating testos-
terone or dehydroepiandrosterone sulfate or an increase in the free
androgen index above the 95th percentile of the control values derived
from the nonhirsute, nonacneic women having regular menses who
were not receiving hormonal therapy. PCOS was present in 10 (6.5%),
hirsutism was present in 11 (7.1%), and acne was present in 19
(12.3%) of the 154 women. Our results demonstrate a 6.5% prevalence
of PCOS, as defined, in a minimally biased population of Caucasian
women from Spain. The polycystic ovary syndrome, hirsutism, and
acne are common endocrine disorders in women. (J Clin Endocrinol
Metab 85: 2434–2438, 2000)
THE POLYCYSTIC ovary syndrome (PCOS) appears to beone of the most common endocrine disorders of
women (1). Moreover, PCOS is associated with significant
reproductive, endocrine, metabolic, and cardiovascular,
morbidity (2). However, the data regarding the prevalence of
this disorder are surprisingly scarce and are biased by the
different criteria used to define the disease. When detected
by sonography, polycystic ovaries are present in 14–23% of
unselected women (3–6). However, a significant proportion
of these patients are asymptomatic (7), whereas not all pa-
tients with hyperandrogenic anovulation have polycystic
ovaries on ultrasound examination (6–9), suggesting that
ultrasound is a nonspecific marker for the diagnosis of PCOS.
At present, the diagnosis of PCOS is usually based on the
criteria derived from the 1990 NIH/NICHHD conference
(10): 1) menstrual dysfunction, 2) clinical hyperandrogenism
(hirsutism, acne, androgenic alopecia) and/or hyperandro-
genemia, and 3) exclusion of other related disorders, such as
hyperprolactinemia, nonclassic adrenal hyperplasia, or thy-
roid disease. Using these criteria, Knochenhauer et al. (11)
reported a 4.0% prevalence of PCOS in the southeastern U.S.,
namely, Birmingham, AL. This carefully designed study in-
volved both White and Black women and avoided any sig-
nificant bias in the selection of the participants. Further, a
similar 6.8% prevalence of PCOS has been recently reported
in the Greek island of Lesbos (12).
In the present study we estimated the prevalence of PCOS
and hirsutism in 154 consecutive Caucasian women from
Madrid, Spain, using a design similar to that used by
Knochenhauer et al. (11). To avoid any selection of the pop-
ulation, all of the women studied here were consecutive




The study population consisted in Caucasian female blood donors
reporting to the Department of Hematology of the Hospital Ramón y
Cajal from May to June 1999. The presence of hirsutism was scored in
every woman by a single investigator, using a modification of the
Ferriman-Gallwey method (13), quantitating the presence of terminal
hairs over nine body areas (i.e. upper lip, chin, chest, upper and lower
abdomen, upper and lower back, upper arms, and thighs). The presence
or absence of acne and androgenic alopecia was recorded, and weight,
height, and waist and hip circumferences were measured.
A history form was completed, including menstrual dating and ir-
regularity, hirsutism and acne, reproductive history, gynecological his-
tory, use of medication including oral contraceptive pills, and family
history of male pattern premature baldness, carbohydrate intolerance,
and arterial hypertension. In women who were receiving hormonal
therapy, their menstrual history before treatment and the reason for
treatment were recorded. Women with physiological menopause—
present or past symptoms of hypoestrogenism such as hot flushes and
vaginal dryness, emotional lability, and menstrual abnormalities in a
woman older than 45 yr (14)—were excluded from the study. None of
the subjects was younger than 18 yr old, which is the minimum legal age
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for blood donation in Spain. In those women who were found to be
suitable blood donors, serum samples were obtained, and were stored
at 220 C until assayed. When women were finally not accepted as blood
donors because of present anemia or previous history infectious hep-
atitis, no serum samples were obtained.
The study was approved by the institutional review board of the
Hospital Ramón y Cajal, and written informed consent was obtained
from all the subjects.
Assays
Serum samples were analyzed for total testosterone (T), sex hormone-
binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS),
progesterone (P4), LH, FSH, and estradiol (E2). In women who matched
the criteria for PCOS, PRL, TSH, and 17-hydroxyprogesterone (17-OHP)
were also measured to exclude hyperprolactinemia, hypothyroidism,
and nonclassic 21-hydroxylase deficiency, respectively.
Total T, SHBG, DHEAS, P4, LH, FSH, E2, PRL, and TSH were mea-
sured, each hormone in a single assay, using an automated immuno-
chemiluminescence method (Immulite, Diagnostic Products, Los Ange-
les, CA). 17-OHP was measured by direct RIA using a commercially
available kit (ImmuChem, ICN Biomedicals, Inc., Costa Mesa, CA) in a
single assay. The mean intraassay coefficients of variation were as fol-
lows: 7.4% for T, 6.5% for SHBG, 6.9% for DHEAS, 8.2% for P4, 5.7% for
LH, 6.4% for FSH, 9.3% for E2, 6.2% for PRL, 7.1% for TSH, and 9.5% for
17-OHP. The free androgen index (FAI) was calculated using the for-
mula [T (nmol/L) 3 100]/SHBG (nmol/L)].
Criteria for the definition of PCOS
As stated above, PCOS was defined by the presence of 1) menstrual
dysfunction, 2) clinical hyperandrogenism and/or hyperandrogenemia,
and 3) exclusion of other disorders (10). Menstrual dysfunction was
considered when the women had oligomenorrhea, defined by more than
six cycles with a length of more than 35 days, and/or when the patient
had not had any menstrual bleeding for 3 consecutive months during the
last year. Clinical hyperandrogenism was defined by the presence of
hirsutism, represented by a hirsutism score of 8 or more, persistence of
acne during the third decade of life or later, or the presence of androgenic
alopecia. No attempts were made to grade the severity of acne or alo-
pecia. Hyperandrogenemia was defined by a circulating T and DHEAS
levels and/or FAI higher than the 95th percentile for the women studied
here who had no clinical evidence of hyperandrogenism or menstrual
disturbances and who were not taking hormonal medication nor had
had previous oophorectomy or hysterectomy. Hyperprolactinemia, thy-
roid dysfunction, and nonclassic 21-hydroxylase deficiency were ex-
cluded in all of the women who achieved the other criteria for the
diagnosis of PCOS.
Statistical analysis
The results are expressed as the mean 6 sd in the text and tables.
One-way ANOVA followed by the least significant difference test were
used to compare the means of the different groups of women. A x2 test
was used for discontinuous variables. P , 0.05 was considered signif-
icant. A statistical software package was used to perform the analyses
(SPSS for the Macintosh, version 6.1.1, SPSS, Inc., Chicago, IL).
Results
One hundred and fifty-four women agreed to participate
in the study. Clinical variables were evaluated in all of them,
including hirsutism scores and menstrual history, and in 145
women serum samples were also obtained. Mean age, body
mass index , and waist to hip ratios were 33.1 6 9.1 yr, 23.8 6
3.2 kg/m2, and 0.79 6 0.06, respectively. Eight women (5.2%)
showed a hirsutism score of 8 or more, and 3 other subjects,
with hirsutism scores of 2, 3, and 5, were receiving hormonal
treatment for hirsutism. Therefore, 11 of the 154 women
(7.1%) may be considered to have hirsutism. None of the
other subjects had a history of treated hirsutism. Persistence
of acne after the second decade of life was found in 19 women
(12.3%). None of the women had androgenic alopecia.
Thirty-one women were taking oral contraceptive pills,
including those 3 patients being treated for hirsutism and
another 3 subjects with a hirsutism score of 8 or more who
were taking the pill solely as contraceptive. Seventy-nine
women did not have hirsutism, acne, or menstrual distur-
bances; were not receiving hormonal therapy, and had no
history of previous hysterectomy or oophorectomy. These
women composed the normal population from which the
upper control 95th percentile values for androgens were
calculated: T, 2.5 nmol/L; FAI, 3.9; and DHEAS, 11.9
mmol/L.
Of the whole population studied, 30 women (19.5%) had
a history consistent with oligomenorrhea, and 13 fulfilled the
2 first criteria (oligomenorrhea and evidence of hyperandro-
genism) for the diagnosis of PCOS. However, hyperpro-
lactinemia, defined by serum PRL more than 24 mg/L, was
present in 3 of these women (serum PRL levels were 26.8,
50.8, and 80.4 mg/L, respectively), and therefore, the diag-
nosis of PCOS was sustained in only 10 of the 154 subjects
studied (6.5%). In 9 of the 10 patients diagnosed with PCOS,
serum samples were available. None of these women had
17-OHP levels above 6.0 nmol/L, which is the cut-off level
suggested for maximum sensitivity in the detection of non-
classic adrenal hyperplasia using 17-OHP measurements ob-
tained from nonearly morning samples (15). Further, none of
these patients had abnormal serum TSH levels, ruling out
thyroid dysfunction.
The clinical characteristics of the 10 patients who met all
of the criteria for the diagnosis of PCOS are described in
Table 1. The diagnosis of PCOS was based on the presence
of oligomenorrhea and hirsutism in 4 of the 10 patients.
Hyperandrogenemia was present in 1 of them, who also
presented acne; another patient was taking oral contracep-
tive pills, and her normal androgen levels might represent
the effect of such treatment on ovarian function. In another
patient, serum androgen levels were not measured. The di-
agnosis of PCOS was solely sustained on the basis of oligo-
menorrhea and hyperandrogenemia in 4 patients (1 of these
women had acne, but was 18 yr old) and of oligomenorrhea,
acne, and hyperandrogenemia in 2 patients.
In addition to 7 of the women diagnosed with PCOS and
the women with hyperprolactinemia, hyperandrogenemia
was present in another 19 women who did not have oligo-
menorrhea. Thirteen of them had no clinical manifestations
of hyperandrogenism, but 1 of these women was taking oral
contraceptive medication. Five had acne (1 was taking a
contraceptive pill), and 1 had hirsutism.
As stated above, of the 11 patients considered to have
hirsutism, 4 were diagnosed as having PCOS, 2 subjects had
oligomenorrhea and hyperprolactinemia, and 5 had hirsut-
ism with regular menstrual cycles. Of the latter, hyperan-
drogenemia was present in only 1 woman, but another 3
were taking oral contraceptive pills, which may have low-
ered their androgen concentrations.
We then compared the clinical data and serum androgen
concentrations of the women diagnosed with PCOS with
those of 1) the women with hyperandrogenemia and regular
menstrual cycles, 2) the women who presented with idio-
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pathic hirsutism and/or acne but did not have oligomenor-
rhea or hyperandrogenemia, and 3) the women without clin-
ical hyperandrogenism who had normal serum androgen
levels, representing the nonhyperandrogenic group. This
group of nonhyperandrogenic women did not completely
match the group of women used to define the normal ranges
for serum androgens. The latter was selected on a clinical
basis before knowing the serum androgen concentrations,
and therefore, some of these women actually had increased
levels of the androgens measured. These subjects were in-
cluded in the group of women with hyperandrogenemia and
regular menstrual cycles for this analysis. Conversely, some
women with nonhyperandrogenic oligomenorrhea, who
could not be used to define the normal ranges for serum
androgens, were included in the group of nonhyperandro-
genic women. Because of the profound effects of oral con-
traceptives on serum androgen and SHBG levels, women
taking these medications were excluded from these compar-
isons. Also, the three patients in whom PCOS was excluded
because of hyperprolactinemia were not included in this
analysis.
Women with PCOS and women with hyperandrogenemia
and regular cycles were younger than women with idio-
pathic hirsutism and/or acne without oligomenorrhea or
hyperandrogenemia and nonhyperandrogenic women (Ta-
ble 2). The higher hirsutism scores were found in women
with PCOS, but as a group, women with idiopathic hirsutism
and/or acne without oligomenorrhea or hyperandrogen-
emia had also higher hirsutism scores than nonhyperandro-
genic women (Table 2). There were no differences among the
groups in body mass index, waist to hip ratios, ages at men-
arche and pubarche, and number of abortions (Table 2). On
the contrary, women with hyperandrogenemia and regular
cycles had fewer pregnancies and infants born than the non-
hyperandrogenic group or the women with idiopathic hir-
sutism and/or acne without oligomenorrhea or hyperandro-
genemia (Table 2).
Women with hyperandrogenemia and regular cycles had
higher T levels than any of the other groups (Table 2). Serum
T concentrations were also increased in PCOS patients com-
pared to women with idiopathic hirsutism and/or acne with-
out oligomenorrhea or hyperandrogenemia and to nonhy-
perandrogenic women (Table 2). The FAI and serum DHEAS
levels were increased to a similar extent in women with
hyperandrogenemia and regular cycles and in PCOS patients
compared to patients with women with idiopathic hirsutism
and/or acne without oligomenorrhea or hyperandrogen-
emia and to nonhyperandrogenic women (Table 2). Women
with PCOS had decreased SHBG levels compared to women
with idiopathic hirsutism and/or acne without oligomenor-
rhea or hyperandrogenemia and to nonhyperandrogenic
women. There were no differences in serum LH, FSH, E2, and
P4 levels among the groups (Table 2).
Finally, none of the subjects with hyperandrogenic disor-
ders had a history of carbohydrate intolerance or hyperten-
sion (their blood pressure measurements were normal at the
time of the study), but no further effort was made to diagnose
these disorders. Moreover, no significant differences were
found among the groups of subjects in the proportion of
women with family history of diabetes mellitus, arterial hy-
pertension, or male pattern premature baldness (Table 2).
Discussion
Although PCOS is believed to be one of the most common
endocrine disorders of women (1, 2), there are very few data
regarding its prevalence in the female population. As stated
above, the present endocrine definition of PCOS is based on
several criteria, accepted by the NIH/NICHHD-sponsored
conference in 1990 (10). To our knowledge, there are only two
recent studies estimating the prevalence of PCOS using these
criteria. Knochenhauer et al. (11) reported an overall 4.0%
prevalence of PCOS in women from the U.S. (4.7% in White
women and 3.4% in Black women), and Diamanti-Kandara-
kis et al. reported a 6.8% prevalence of PCOS in the Greek
island of Lesbos (12).
Using strict NIH/NICHHD criteria, we found a 6.5% prev-
alence of PCOS in Caucasian women from Madrid, Spain.
However, moderate increases in serum PRL levels are fre-
quently found in women with hyperandrogenism and may
also result from the stress of blood sampling and from treat-
ment with oral contraceptives. Without excluding the three
patients who were considered as not having PCOS because
of mild to moderate hyperprolactinemia, the prevalence of
PCOS in our series might have been as high as 8.4%.
Our study share many characteristics with that by
Knochenhauer et al. (11), allowing direct comparison be-
tween their results and our present findings. Considering










score Acne Oligomenorrhea T (nmol/L) FAI
DHEAS
(mmol/L) OC
15 24 22.3 0.80 18 No Yes ND ND ND No
37 18 23.4 0.87 1 Yes Yes 1.2 5.1a 15.6a No
49 22 32.9 0.82 17 Yes Yes 2.9a 17.0a 12.2a No
74 30 27.5 0.88 3 Yes Yes 1.3 6.7a 8.6 No
105 22 25.3 0.79 6 No Yes 1.1 4.5a 5.8 No
110 27 24.2 0.84 21 No Yes ,0.7 2.1 6.9 No
115 23 19.3 0.77 9 No Yes ,0.7 0.5 6.2 Yes
116 34 20.6 0.82 1 Yes Yes 1.8 2.4 12.1a No
118 20 20.9 0.69 1 No Yes 1.4 3.7 15.3a No
149 27 29.1 0.73 4 No Yes 3.1a 11.0a 16.8a No
BMI, Body mass index; T, circulating total testosterone; FAI, free androgen index; DHEAS serum dehydroepiandrosterone sulfate levels;
OC, oral contraceptive pills; ND, not determined (blood samples from this woman were not obtained).
a Greater than the upper control 95th percentile value.
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that all of the women who entered our present study were
Caucasian, the size of the sample we studied was similar to
the number of White women included in the study from
Knochenhauer et al. (11) and was adequate to estimate the
prevalence of PCOS as previously discussed (11). Moreover,
both studies were designed to minimize bias of the sample
population studied.
We prospectively included consecutive female blood do-
nors attending our hospital during a limited period of time.
We believe that blood donors are an especially adequate
sample of the population for several reasons: 1) they were
usually healthy people, not seeking medical care for any
reason at the time of the study; 2) as in Spain blood donation
is not rewarded in any way, there is no bias derived from the
socio-economic background; 3) blood donors have mixed
ethnic origins, representing the population where they live;
4) there is no preselection of blood donors, as they come to
the hospital without scheduling; and 5) it is easy to obtain
blood samples from them. Finally, as in the study from
Knochenhauer et al. (11), we defined the normative data for
serum androgens from the group of nonhirsute, nonacneic,
eumenorrheic women of the study population who were not
taking hormonal preparations. On the contrary, as occurred
to Knochenhauer et al. (11) in their study, we were not able
to control precisely for the time of the day of serum sampling
or for the day of the menstrual cycle. However, as elegantly
discussed by Knochenhauer et al. (11), none of these factors
has been demonstrated to have a significant impact on the
clinical value of circulating androgens.
Madrid is representative of the population of Spain, as its
present population was conformed during the last 50 yr by
immigrants from all areas of the country. All of the women
studied here were Caucasian, although it should be noted
that the population from Spain has important Jewish and
Arabic influences dating back to the Middle Ages, as occurs
with most Mediterranean countries.
Minor differences in the design of the study may explain
the slightly higher prevalence of PCOS found in Spain (6.5%)
compared to White women from Alabama (4.7%). We de-
fined clinical hyperandrogenism by the presence of hirsutism
and/or acne, whereas Knochenhauer et al. (11) only consid-
ered hirsutism for the diagnosis of PCOS. Although in none
of our PCOS patients did the diagnosis rely solely on acne
and oligomenorrhea, in the study by Knochenhauer et al. (11),
the inclusion of acne as a sign of hyperandrogenism would
have increased the prevalence of PCOS in White women to
5.4%. Further, we used less stringent criteria for the defini-
tion of oligomenorrhea, which might be responsible for the
1% increase in the prevalence of PCOS in Spain compared to
Alabama.
However, we found higher prevalences of hirsutism, as
defined by a hirsutism score of 8 or more, and acne in Spanish
women (7.1% and 12.3%, respectively) compared to White
women from Alabama (2.8% and 5.2%, respectively) (11),
suggesting that hyperandrogenic disorders might be more
prevalent in Spain. As reviewed by Knochenhauer et al. (11),
older studies have reported excess “hairiness” in 5–15% of
consecutive Caucasian women (16–20), and Ferriman and
TABLE 2. Clinical data and serum androgen concentrations of women diagnosed with PCOS as compared to women with
hyperandrogenemia and regular menses, women who presented with idiopathic hirsutism and/or acne, but did not have oligomenorrhea or
hyperandrogenemia, and nonhyperandrogenic women, excluding women taking oral contraceptives




regular menses (n 5 17)
Idiopathic hirsutism
and/or acne (n 5 9) Statistics
Age (yr) 36.3 6 9.1 24.9 6 5.1a 26.4 6 7.8a 35.0 6 5.4 ,0.001
BMI (kg/m2) 24.2 6 3.3 25.1 6 4.1 24.4 6 2.9 22.8 6 1.6 NS
Waist to hip ratio 0.80 6 0.06 0.80 6 0.06 0.81 6 0.05 0.79 6 0.06 NS
Hirsutism score 1.8 6 1.7 8.0 6 8.2b 3.2 6 3.4 3.9 6 2.4c ,0.001
Pregnancies 1.5 6 1.5 0.7 6 0.9 0.5 6 1.3b 1.9 6 1.3 ,0.050
Born 1.2 6 1.1 0.6 6 0.9 0.4 6 0.8b 1.4 6 0.9 ,0.010
Abortions 0.4 6 0.8 0.1 6 0.3 0.2 6 0.7 0.7 6 1.1 NS
Pubarche (yr) 11.8 6 1.5 11.8 6 0.7 11.2 6 1.3 10.9 6 1.0 NS
Menarche (yr) 12.6 6 1.6 13.0 6 1.4 12.5 6 1.4 11.6 6 1.3 NS
FHDM (%) 24 44 35 22 NS
FHHT (%) 33 22 59 11 NS
FHMPPB (%) 14 22 18 33 NS
Total testosterone (nmol/L) 1.0 6 0.4 1.7 6 0.9a 2.5 6 1.0b 0.9 6 0.5 ,0.001
Free androgen index 1.8 6 1.0 6.5 6 5.1a 5.3 6 3.9a 1.3 6 0.5 ,0.001
SHBG (nmol/L) 69 6 40 32 6 18a 60 6 29 80 6 40 ,0.050
DHEAS (mmol/L) 5.8 6 2.6 11.6 6 4.2a 10.9 6 5.5a 5.0 6 1.9 ,0.001
LH (IU/L) 10.1 6 11.1 8.1 6 5.2 12.6 6 12.9 6.1 6 3.0 NS
FSH (IU/L) 13.3 6 20.7 7.4 6 2.9 7.2 6 2.9 7.0 6 4.8 NS
Estradiol (pmol/L) 330 6 257 217 6 147 360 6 290 297 6 209 NS
Progesterone (nmol/L) 17 6 19 7 6 13 9 6 9 18 6 17 NS
BMI, Body mass index; FHDM, percentage of subjects with family history of diabetes mellitus; FHHT, percentage of subjects with family
history of arterial hypertension; FHMPPB, percentage of subjects with family history of male pattern premature baldness; SHBG, circulating
sex hormone-binding globulin levels; DHEAS, serum dehydroepiandrosterone sulfate levels. Because of the profound effects of oral contra-
ceptives on serum androgens and SHBG, women taking these medications were excluded for comparisons between groups. Serum samples were
obtained from 80 women from the nonhyperandrogenic group, 8 women from the PCOS group, 17 women from the hyperandrogenemia group,
and 8 women from the idiopathic hirsutism and/or acne group, who did not have oligomenorrhea or hyperandrogenemia.
a Compared to the group of nonhyperandrogenic women and to women with idiopathic hirsutism and/or acne who did not have oligomenorrhea
or hyperandrogenemia.
b Compared to all the other groups.
c Compared to the group of nonhyperandrogenic women.
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Gallwey (21) found that only 5% of the general population
had a hirsutism score of 6 or greater in the original study. The
prevalence of hirsutism in our series does not appear to be
exaggerated with respect to these previous studies.
As stated above, Diamanti-Kandarakis et al. (12) recently
found a 6.8% prevalence of PCOS in the Greek island of
Lesbos. However, this study, which in addition to evaluating
the prevalence of PCOS was designed to evaluate hormonal
and metabolic abnormalities and family history of metabolic
disorders in these patients, presented significant method-
ological differences compared to our present study and that
by Knochenhauer et al. (11). First, instead of studying un-
selected women, the sample of the female population of
Lesbos was recruited after a large scale informational
campaign offering free medical examination by an endocri-
nologist (12). Second, the definition of PCOS used by
Diamanti-Kandarakis et al. (12) included only women with
oligomenorrhea and hyperandrogenemia. If women with
clinical hyperandrogenism, normal androgen levels, and oli-
gomenorrhea were also considered to have PCOS, as in our
present study and that by Knochenhauer et al. (11), the prev-
alence would have been 10.4% (12). Moreover, as free T was
the only androgen measured, the prevalence of PCOS in
Lesbos would have been even higher if other serum andro-
gens were measured.
In addition to women with PCOS, Diamanti-Kandarakis et
al. (12) found a 29% prevalence of idiopathic hirsutism in
women from Lesbos, an exaggerated figure in view of the
prevalences in Madrid, Alabama (11), and elsewhere (16–20).
Taken together with the statement of the authors that their
recruitment of patients was not fully randomized (12), these
high prevalences of PCOS and hirsutism in Lesbos suggest
a selection bias in the studied population.
In our present study, women with PCOS and women with
hyperandrogenemia and regular cycles were significantly
younger than women with idiopathic hirsutism and/or acne
without oligomenorrhea or hyperandrogenemia and than
women without evidence of hyperandrogenic disorders. The
older woman diagnosed with PCOS was 34 yr old in our
series and 29 yr old in that by Knochenhauer et al. (11).
Further, a recent study reported that the finding of polycystic
ovaries by sonography is also much more common in un-
selected women 35 yr old or younger (21.6% prevalence) than
in women older than 36 yr (7.8% prevalence) (6). In agree-
ment, our previous results in a different series of hirsute
patients showed that for a similar severity of hyperandro-
genic symptoms, younger patients had higher androgen lev-
els of ovarian and/or adrenal origin than older women (22).
These findings may be derived from the well known de-
cline of adrenal androgens with age (23), but might also
indicate that age, possibly reflecting the influence of growth
factors on adrenal and ovarian function, modulates the clin-
ical and biochemical expression of hyperandrogenism. Def-
inite proof of this point will require studies specifically de-
signed to address this question. Finally, we did not found any
influence of obesity or abdominal distribution of fat on the
hyperandrogenic disorders studied here.
In conclusion, we found a 6.5% prevalence of PCOS, as
defined by the criteria derived from the NIH/NICHHD-
sponsored conference in 1990, in a minimally biased popu-
lation of Caucasian women from Spain. PCOS and hirsutism
are common endocrine disorders in women, especially at
younger ages.
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